S.E.E.D. Planning Group LLC Grows Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

S.E.E.D. Planning Group LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,178 shares of the medical research company’s stock after purchasing an additional 371 shares during the quarter. Thermo Fisher Scientific comprises approximately 2.2% of S.E.E.D. Planning Group LLC’s investment portfolio, making the stock its 19th biggest position. S.E.E.D. Planning Group LLC’s holdings in Thermo Fisher Scientific were worth $5,916,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. WCM Investment Management LLC raised its position in Thermo Fisher Scientific by 0.3% in the 4th quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock valued at $527,524,000 after purchasing an additional 2,928 shares in the last quarter. Summa Corp. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $418,000. Phoenix Holdings Ltd. raised its position in shares of Thermo Fisher Scientific by 21.4% during the 3rd quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock worth $4,750,000 after acquiring an additional 1,654 shares in the last quarter. S. R. Schill & Associates raised its position in shares of Thermo Fisher Scientific by 106.3% during the 4th quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock worth $816,000 after acquiring an additional 792 shares in the last quarter. Finally, Tsfg LLC raised its position in shares of Thermo Fisher Scientific by 8.3% during the 4th quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock worth $132,000 after acquiring an additional 19 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded up $2.22 during trading on Friday, reaching $553.00. The company’s stock had a trading volume of 6,150,885 shares, compared to its average volume of 1,473,906. The business has a 50 day moving average price of $574.84 and a 200-day moving average price of $562.59. The company has a market capitalization of $211.09 billion, a P/E ratio of 35.45, a price-to-earnings-growth ratio of 2.57 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The company had revenue of $10.35 billion during the quarter, compared to analysts’ expectations of $10.14 billion. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Friday, June 14th will be given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date is Friday, June 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Insider Activity

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the sale, the senior vice president now owns 13,083 shares of the company’s stock, valued at $7,430,359.02. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $567.28, for a total value of $5,672,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,238,340.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the sale, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. Insiders sold a total of 22,000 shares of company stock valued at $12,532,780 over the last quarter. Company insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on TMO. Deutsche Bank Aktiengesellschaft raised their price target on Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a research note on Thursday, April 25th. Citigroup began coverage on Thermo Fisher Scientific in a research note on Monday, March 18th. They set a “neutral” rating and a $620.00 price target on the stock. The Goldman Sachs Group raised their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Robert W. Baird dropped their price target on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research note on Thursday, April 25th. Finally, HSBC lifted their target price on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. Five analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $607.06.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.